Notice: This company has been marked as potentially delisted and may not be actively trading. Trillium Therapeutics (TRIL) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period When You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) StockJuly 30, 2024 | finance.yahoo.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 10, 2023 | businesswire.comMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | benzinga.comThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodJuly 31, 2023 | uk.finance.yahoo.comWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'April 26, 2023 | msn.comLeukemia Therapeutics Global Market Report 2023April 4, 2023 | uk.finance.yahoo.comRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckMarch 28, 2023 | finance.yahoo.comFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular CarcinomaOctober 19, 2022 | nz.finance.yahoo.comCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentSeptember 14, 2022 | seekingalpha.comZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of DirectorsSeptember 12, 2022 | nz.finance.yahoo.comPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is NeededAugust 17, 2022 | seekingalpha.com10 Psychedelics CEOs To Pay Attention To In 2022June 22, 2022 | markets.businessinsider.comPfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?May 20, 2022 | edition.cnn.com3 Dividend Stocks That We'd Buy Without Any HesitationMarch 20, 2022 | nasdaq.comMindset Pharma CEO, James Lanthier, Issues Letter to ShareholdersMarch 17, 2022 | stockhouse.comNeonMind Biosciences Inc.: NeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, OntarioFebruary 17, 2022 | finanznachrichten.deCD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035 - ResearchAndMarkets.comDecember 14, 2021 | au.finance.yahoo.com3 Firms Draw Up Pfizer's $6.7B Arena Pharmaceuticals BuyDecember 14, 2021 | law360.comTrillium Therapeutics (NASDAQ:TRIL) Lifted to "Buy" at Zacks Investment ResearchZacks Investment Research raised Trillium Therapeutics from a "hold" rating to a "buy" rating and set a $20.00 target price for the company in a research report on Wednesday.November 17, 2021 | marketbeat.comTrillium Therapeutics (NASDAQ:TRIL) Downgraded to "Hold" at BenchmarkBenchmark lowered Trillium Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday.November 17, 2021 | marketbeat.comTrading was temporarily halted for "TRIL" at 07:11 PM with a stated reason of "News pending."November 17, 2021 | marketbeat.comIs Trillium Therapeutics Inc. (TRIL) A Good Stock To Buy?October 25, 2021 | finance.yahoo.comTrillium Therapeutics (NASDAQ:TRIL) Upgraded to "Buy" at Zacks Investment ResearchZacks Investment Research raised shares of Trillium Therapeutics from a "sell" rating to a "buy" rating and set a $20.00 target price for the company in a report on Tuesday.October 19, 2021 | marketbeat.com2 Top Healthcare Stocks That Could Be Bought Out in 2022October 16, 2021 | msn.comBRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14October 13, 2021 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the FirmSeptember 22, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Trillium Therapeutics, Inc. - TRILSeptember 11, 2021 | finance.yahoo.comMoore Kuehn Encourages TRIL, OPA, HRC, and CXP Investors to Contact Law FirmSeptember 9, 2021 | benzinga.comSHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and SIC Shareholders About Its Ongoing InvestigationsSeptember 7, 2021 | finance.yahoo.comWhy Investors Should Love Pfizer's Acquisition of TrilliumSeptember 4, 2021 | finance.yahoo.comAugust M&A roundup: Trillium's redemption and Reebok's $2.5B saleSeptember 1, 2021 | bizjournals.comForget Trillium Therapeutics Stock (TSX:TRIL): Buy These Pharma Stocks Instead!August 31, 2021 | ca.finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Trillium Therapeutics, Inc. BuyoutAugust 24, 2021 | finance.yahoo.comTrillium Therapeutics (NASDAQ:TRIL) Downgraded by JMP Securities to "Market Perform"JMP Securities downgraded shares of Trillium Therapeutics from an "outperform" rating to a "market perform" rating in a report on Tuesday.August 24, 2021 | marketbeat.comTRILLIUM THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Trillium Therapeutics Inc. - TRILAugust 23, 2021 | finance.yahoo.comChip shortage to worsen, Trillium pops 180% after Pfizer buyout, Coinbase reassures on stablecoinsAugust 23, 2021 | finance.yahoo.comTrillium Therapeutics shares soar on Pfizer’s $2.26B dealAugust 23, 2021 | msn.comPfizer To Buy Trillium Therapeutics For $18.50/Shr Cash - Quick FactsAugust 23, 2021 | nasdaq.comTrillium Therapeutics soars 200% after Pfizer inks deal to buy cancer-drug company for $2.3 billionAugust 23, 2021 | msn.comPfizer to buy cancer drug developer Trillium in $2.3 billion dealAugust 23, 2021 | finance.yahoo.comTrillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billionAugust 23, 2021 | finance.yahoo.comUPDATE 2-Pfizer to buy cancer drug developer Trillium in $2.3 bln dealAugust 23, 2021 | finance.yahoo.comTrillium Therapeutics Reports Second Quarter 2021 Operating and Financial ResultsAugust 13, 2021 | finance.yahoo.comTrillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid LeukemiaAugust 9, 2021 | finance.yahoo.com Get Trillium Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] TRIL Media Mentions By Week TRIL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRIL News Sentiment▼0.000.47▲Average Medical News Sentiment TRIL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRIL Articles This Week▼00▲TRIL Articles Average Week Get Trillium Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Jazz Pharmaceuticals News Ascendis Pharma A/S News Legend Biotech News Madrigal Pharmaceuticals News Elanco Animal Health News Blueprint Medicines News Nuvalent News Corcept Therapeutics News Viking Therapeutics News Cytokinetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRIL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trillium Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
